ELI LILLY & Co · NYSE · Pharmaceutical Preparations
Lilly raised its 2026 revenue guidance to $91.0 billion to $92.0 billion, while its non-GAAP EPS guidance was lowered to $35.00 to $36.00 from $35.50 to $36.50 after acquired IPR&D charges.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 17, 2026 | Patrik Jonsson EVP & President, LLY Int'l | Sold 10b5-1 plan | 6,500 | $1,175.10 | $7.64 million |
| Aug. 10, 2026 | Donald A. Zakrowski SVP, Finance, & CAO | Sold 10b5-1 plan | 2,000 | $1,185.01 | $2.37 million |
| Aug. 7, 2026 | Anat Hakim EVP, GC & Secretary · indirect | Sold 10b5-1 plan | 5,000 | $1,190.00 | $5.95 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedEli Lilly Q3 2026 non-GAAP EPS $7.48 beats $6.61 consensus on $24.4 billion revenue; raises 2026 revenue guidance to $91.0-$92.0 billion